血清CEA CA199 CA125水平与肺腺癌化疗疗效的关联性探讨

Correlation between levels of serum CEA,CA199 and CA125 and chemotherapeutic effect on lung adenocarcinoma

目的检测晚期肺腺癌患者化疗治疗前后的血清癌胚抗原(CEA)、糖类抗原19-9(CA199)、糖类抗原125(CA125)水平,探讨肿瘤标记物与近期疗效的相关性。方法收集该院2012-01~2017-01收治的64例晚期肺腺癌患者,接受培美曲塞联合顺铂(AP方案)化疗,检测治疗前及化疗2周期后血清CEA、CA199、CA125水平,并行影像学疗效评价。结果64例肺腺癌患者AP方案化疗后完全缓解1例,部分缓解22例,疾病稳定22例,疾病进展19例。完全缓解及部分缓解患者治疗后CEA、CA199、CA125水平显著降低(P<0.05),疾病稳定患者治疗前后CEA、CA199、CA125水平差异无统计学意义(P>0.05),疾病进展患者治疗后CEA、CA199、CA125水平显著增高(P<0.05);完全缓解及部分缓解患者治疗前CEA、CA199、CA125水平显著高于疾病稳定、疾病进展患者(P<0.05),疾病稳定患者治疗前CEA、CA199、CA125水平与疾病进展患者差异无统计学意义(P>0.05)。结论血清CEA、CA199、CA125水平变化对预测肺腺癌患者化疗后近期疗效有一定价值,血清CEA、CA199、CA125高水平患者预示可能有较好的化疗效果。

Objective To detect the levels of serum carcinoembryonic antigen(CEA), carbohydrate antigen 19-9(CA199) and carbohydrate antigen 125(CA125) in the patients with advanced lung adenocarcinoma before and after chemotherapy, and to explore the correlation between the tumor markers and short-term curative effects. Methods Sixty-four patients with advanced lung adenocarcinoma who were admitted to Henan Hongli Hospital from January 2012 to January 2017 were treated with the chemotherapy of pemetrexed in combination with cisplatin(AP regimen). The levels of serum CEA, CA199 and CA125 were detected before and two weeks after chemotherapy. The evaluation on imaging efficacy was conducted. Results Of the 64 patients receiving AP regimen, 1 case got complete remission, 22 partial remission, 22 stable disease and 19 disease progression. The levels of CEA, CA199 and CA125 in the patients with complete remission or partial remission were significantly decreased( P <0.05), while the levels of CEA, CA199 and CA125 in the patients with stable disease had no significant differences before and after treatment( P >0.05). The levels of CEA, CA199 and CA125 in the patients with disease progression were significantly increased after treatment( P <0.05). Before treatment, the levels of CEA, CA199 and CA125 in the patients with complete remission or partial remission were significantly higher than those in the patients with stable disease or disease progression( P <0.05). Before treatment, there were no significant differences in the levels of CEA, CA199 and CA125 between the patients with stable disease and those with disease progression( P >0.05). Conclusion The changes of serum CEA, CA199 and CA125 levels have certain value in predicting the short-term curative effect for the patients with lung adenocarcinoma after chemotherapy. The patients with high serum levels of CEA, CA199 and CA125 may have better chemotherapeutic effect.